MannKind

MannKind Stock-Based Compensation

The Stock-Based Compensation (SBC) of MannKind (MNKD) as of Nov 18, 2026 is 24.20 M USD. In the previous year, Stock-Based Compensation (SBC) was 21.36 M USD — a change of 13.28% (higher).

Stock-Based Compensation

24.20 MUSD

YoY

13.28%

Last updated:

Stock-Based Compensation (SBC) of MannKind is 2025 24.20 M USD. Stock-Based Compensation (SBC) of MannKind was 2024 21.36 M USD. It decreases by 13.28% higher compared to the previous year.

The MannKind Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2018
6.86 M USD
Jan 1, 2019
6.20 M USD
Jan 1, 2020
6.51 M USD
Jan 1, 2021
12.20 M USD
Jan 1, 2022
13.45 M USD
Jan 1, 2023
17.65 M USD
Jan 1, 2024
21.36 M USD
Jan 1, 2025
24.20 M USD
The MannKind Stock-Based Compensation history
YEARStock-Based CompensationYoY
24.20 MUSD+13.28%
21.36 MUSD+21.02%
17.65 MUSD+31.25%
13.45 MUSD+10.22%
12.20 MUSD+87.38%
6.51 MUSD+4.97%
6.20 MUSD-9.54%
6.86 MUSD+41.47%
4.85 MUSD-5.61%
5.14 MUSD-41.15%
8.73 MUSD-82.06%
48.62 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MannKind Stock analysis

What does MannKind do? MannKind Corp is a biopharmaceutical company that specializes in the development, production, and marketing of inhalable medications. The company was founded in 1991 by renowned scientist Alfred E. Mann and is headquartered in Westlake Village, California. MannKind Corp's history began with its founding in 1991 and the development of technologies for manufacturing injectable drugs. Over the years, the company has continuously evolved its technologies and now specializes in inhalable medications. MannKind Corp offers a wide portfolio of products in various areas, with the main areas being diabetes, lung and respiratory diseases, and cancer and immunology. The company develops and produces innovative medications and inhalation devices that allow patients to fight their illnesses. In particular, MannKind Corp has achieved significant success in the field of diabetes treatment. The company has developed an inhalable insulin solution that allows patients to quickly and easily inhale insulin. This novel insulin preparation called Afrezza was launched in the U.S. market in 2015 and greatly improves the treatment of both Type 1 and Type 2 diabetes. With Afrezza, MannKind Corp has achieved a milestone in medical history. In addition to Afrezza, MannKind is also working on other promising projects such as an inhalable drug for COPD (chronic obstructive pulmonary disease), an inhalable painkiller, and a cancer medication. The company also operates its own research department to develop new drugs and therapies. To realize its business model, the company utilizes partnerships and joint ventures to successfully bring its products to market. For example, it has formed a partnership with Sanofi, a globally leading biopharmaceutical company, to launch Afrezza in Europe. It has also established a partnership with Receptor Life Sciences Inc. in the U.S. to develop an inhalable cannabinoid medication for neuropathic pain. MannKind Corp is a company with ambitious goals and visions. It has already made significant advancements in development and elevated the treatment of diseases to a higher level. With its innovative products and technologies, the company remains a leading player in the biopharmaceutical industry and contributes to improving people's lives. MannKind is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MannKind stock

Stock-Based Compensation (SBC) of MannKind is 24.20 M USD in 2025.

Stock-Based Compensation (SBC) of MannKind changed from 21.36 M USD to 24.20 M USD, representing a 13.28% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) MannKind since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s MannKind historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — MannKind

All Key Metrics — MannKind